ClinicalTrials.gg
RecruitingNCT04184635ANCHORUpdated Jan 14, 2025

Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock

An interventional study of VA-ECMO in Acute Myocardial Infarction and Cardiogenic Shock, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Shock, Cardiogenic with a site in France — 20 open to participants now, 21 under way, 2 of them phase 3. Shock, Cardiogenic · France.

Planned enrollment
4th of 25
400 · median 164
Started
2021
with 5 others
No phase
13 of 62
6 open now
Primary completion
2026-10
later than 7 of 20 live
Registered
25th of 62
by date
Lead sponsor
7 of 62
Assistance Publique - Hôpitaux de Paris

Among the 62 studies in Shock, Cardiogenic with a site in France, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2021, is one of 13 with no phase, reaches primary completion later than 7 of the 20 other live ones, and was the 25th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

20 of the 62 studies in Shock, Cardiogenic with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Shock, Cardiogenic with a site in France, or all of them as a file.
02

Study summary

Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days).

An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.

Read the detailed description

Scientific background

  • Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is used more and more frequently in patients with acute myocardial infarction (AMI) and refractory cardiogenic shock despite the absence of high level scientific evidence to recommend the use of temporary circulatory support devices (TCS) in this setting.TCS support may also benefit to cardiogenic shock patients not initially refractory to conventional medical management since their mortality exceeds 40% and most of deaths are due to the development of refractory cardiogenic shock and multiple organ failure.

The ANCHOR trial is therefore designed to test the hypothesis that VA-ECMO support associated with IABP results in improved outcomes in comparison with optimal medical treatment alone in patients with AMI and cardiogenic shock. An ethical rescue option to VA-ECMO will however be provided to control patients with cardiogenic shock refractory to conventional medical treatment since recent data suggested survival up-to 50% with ECMO support in this setting.

Main objective - To determine if early VA-ECMO combined with IABP support and optimal medical treatment would improve the outcomes of patients with acute myocardial infarction complicated by cardiogenic shock as compared with optimal medical treatment alone.

Scope of the study

  • Patients satisfying all of the Inclusion and Exclusion Criteria will be classified as 'Eligible'. Consent to research will be obtained from a close relative or surrogate for all eligible patients prior to randomization.

Should such a person be absent, eligible patients will be randomized according to the specifications of emergency consent and the patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow.

Randomization will be possible in centers with robust experience in the management of AMI and cardiogenic shock but no on-site ECMO capability providing that an ECMO retrieval team from the nearest ECMO center can establish ECMO no later than 2 hours after randomization.

Before randomization, physicians at the non-ECMO center will check that the ECMO team is immediately available and that an ICU/CCU bed is available at the ECMO center. Thereafter, if the patient is randomized to the ECMO arm, the mobile ECMO retrieval team will travel to the center, initiate VA-ECMO and will rapidly transfer the patient on VA-ECMO to the ECMO center.

Description of experimental ECMO + IABP Arm

  • Protocolized conventional management of cardiogenic shock
  • VA-ECMO will be started as soon as possible
  • For patients randomized at non-ECMO centers, a mobile ECMO team will initiate ECMO at the non-ECMO center and transport the patient to the ECMO center immediately
  • IABP inserted in the contralateral femoral artery (unless technically not possible)
  • ECMO management according to protocol
  • ECMO weaning according to protocol

Description of conventional treatment Arm

  • Protocolized conventional management of cardiogenic shock
  • IABP not recommended. No other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) permitted
  • Rescue VA-ECMO only if one of 1 or 2 or 3 applies:
    1. Refractory cardiogenic shock defined as

      1. Cardiac index \<1.2 l/min/m² or VTI \<6 cm AND
      2. Assessment and correction of hypovolemia AND
      3. (dobutamine ≥15 microg/kg/min + norepinephrine ≥1.5 microg/kg/min) OR epinephrine ≥ 0.75 microg/kg/min
      4. Serum lactate >5 mmol/L or serum lactate increased >50% in the last 6 hours
    1. Uncontrolled lethal arrhythmia despite K >4.5 mmol/l AND Mg >1.0 mmol/l AND Intubation and mechanical ventilation with deep sedation AND IV Loading of amiodarone AND IV xylocaine
    1. Refractory cardiac arrest

Mandatory validation of rescue VA-ECMO by an independent adjudicator.

03

Conditions studied

  • Acute Myocardial Infarction
  • Cardiogenic Shock

Keywords

  • cardiogenic shock
  • VA-ECMO
  • STEMI
  • NSTEMI
  • Intraortic balloon pump
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiogenic shock complicating acute myocardial infarction (STEMI or NSTEMI)
  • Revascularization by PCI for acute myocardial infarction has been performed or is planned in the following 60 minutes
  • Systolic blood pressure \<90 mmHg for >30 min or catecholamine support required to maintain systolic blood pressure >90 mmHg
  • Signs of pulmonary congestion
  • Signs of impaired organ perfusion with at least one of the following:

Altered mental status OR cold, clammy skin and extremities OR oliguria with urine output \<30 ml/h OR serum lactate >2.0 mmol/l

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Pregnancy
  • Onset of shock >24 Hours
  • Shock of other cause (hypovolemic, anaphylactic or vagal shock)
  • Shock due to massive pulmonary embolism
  • Resuscitation >30 minutes
  • No intrinsic heart activity
  • Patient moribund on the day of randomization or SAPS II >90
  • Surgical revascularization for AMI (CABG) planned or already performed prior to randomization
  • Cerebral deficit with fixed dilated pupils or Irreversible neurological pathology
  • Mechanical infarction complication (massive mitral regurgitation, pericardium drainage required, septal ventricular defect)
  • Severe peripheral artery disease or previous aortic or ilio-femoral surgery precluding ECMO and IABP insertion
  • Aortic regurgitation > II
  • Other severe concomitant disease with limited \< 1 year
  • Proven heparin-induced thrombocytopenia
  • ECMO device not immediately available
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Experimental ECMO + IABP Arm

    VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible. An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible).

    Device: VA-ECMO

  • No intervention
    Control Conventional Treatment Arm

    Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.

Interventions

  • DeviceVA-ECMO

    * The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae. * Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France).

06

What researchers measure

Primary outcomes

  1. Treatment failure at Day 30

    Death in the ECMO group and death OR rescue ECMO in the control group

    Time frame: At day 30

Secondary outcomes

  1. Mortality at Day 30

    All-cause mortality at day 30

    Time frame: At day 30

  2. Major Adverse Cardiovascular Events

    Major Adverse Cardiovascular Events are defined as death, stroke (any new neurological symptoms in association with signs of ischemia or hemorrhage in a cranial CT or MRI), recurrent myocardial infarction, need for repeat revascularization (PCI and/or CABG), renal replacement therapy, re-hospitalization for heart failure, escalation to permanent left ventricular assist device (LVAD) or total artificial heart, cardiac transplant.

    Time frame: At day 30

  3. Stroke

    Any new neurological symptoms in association with signs of ischemia or hemorrhage in a cranial CT or MRI

    Time frame: At day 30

  4. Recurrent myocardial infarction

    Recurrent myocardial infarction

    Time frame: At day 30

  5. Need for repeat revascularization with PCI and/or CABG

    Need for repeat revascularization (PCI and/or CABG)

    Time frame: At day 30

  6. Need for renal replacement therapy

    Need for renal replacement therapy

    Time frame: At day 30

  7. Re-hospitalization for heart failure

    re-hospitalization for heart failure

    Time frame: At day 30

  8. Escalation to LVAD or total artificial heart

    Escalation to permanent left ventricular assist device or total artificial heart

    Time frame: At day 30

  9. Cardiac transplantation

    Cardiac transplantation

    Time frame: At day 30

  10. Major bleeding

    Major bleeding (TIMI definition): Any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo MRI) OR Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in hematocrit OR Fatal bleeding (bleeding that directly results in death within 7 d)

    Time frame: At day 30

  11. Red blood cells transfused

    Number of packed red blood cells transfused

    Time frame: At day 30

  12. Serum lactate

    Time to serum lactate normalization

    Time frame: At day 30

  13. Number of days alive without organ failure at day 30

    Number of days alive without organ failure(s) defined with the SOFA score, catecholamine support, mechanical ventilation and renal replacement therapy

    Time frame: At day 30

  14. Durations of ICU stay and hospitalization

    Durations of ICU stay and of hospitalization

    Time frame: At day 30

  15. LV function

    LV function assessed with Doppler echocardiography or magnetic resonance imaging

    Time frame: At day 30

  16. NYHA/INTERMACS status

    NYHA/INTERMACS status

    Time frame: At day 30

  17. ECMO-related complications

    ECMO-related complications (infection at VA-ECMO cannulation sites requiring antibiotics, hemorrhage, limb ischemia requiring surgery, cannula or circuit thrombosis, overt pulmonary edema, thrombocytopenia, gaseous emboli and hemolysis).

    Time frame: At day 30

  18. Treatment failure at one year

    Treatment failure defined as death (all-cause) in the ECMO group and death (all-cause) OR rescue ECMO in the control group.

    Time frame: At one year

  19. Mortality at one year

    All-cause mortality

    Time frame: At one year

  20. Major Adverse Cardiovascular at one year

    MACE, Major Adverse Cardiovascular Events are defined as death, stroke (any new neurological symptoms in association with signs of ischemia or hemorrhage in a cranial CT or MRI), recurrent myocardial infarction, need for repeat revascularization (PCI and/or CABG), renal replacement therapy, re-hospitalization for heart failure, escalation to permanent left ventricular assist device (LVAD) or total artificial heart, cardiac transplant.

    Time frame: At one year

  21. Stroke at one year

    Stroke (any new neurological symptoms in association with signs of ischemia or hemorrhage in a cranial CT or MRI),

    Time frame: At one year

  22. Recurrent myocardial infarction at one year

    Recurrent myocardial infarction between randomization and one year

    Time frame: At one year

  23. PCI and/or CABG at one year

    Repeat revascularization (PCI and/or CABG) between randomization and one year

    Time frame: At one year

  24. Renal replacement therapy at one year

    Need for renal replacement therapy between randomization and one year

    Time frame: At one year

  25. Re-hospitalization for heart failure

    Re-hospitalization for heart failure between randomization and one year

    Time frame: At one year

  26. LVAD at one year

    Escalation to permanent left ventricular assist device (LVAD) or total artificial heart

    Time frame: At one year

  27. Cardiac transplant at one year

    Cardiac transplantation

    Time frame: At one year

  28. Major bleeding at one year

    Major bleeding (TIMI definition): Any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo MRI) OR Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in hematocrit OR Fatal bleeding (bleeding that directly results in death within 7 d)

    Time frame: At one year

  29. NYHA/INTERMACS status at one year

    NYHA/INTERMACS status

    Time frame: At one year

  30. Returned to work at one year

    Rate of patients who returned to work if previously active

    Time frame: At one year

  31. LV ejection fraction at one year

    Latest LV ejection fraction

    Time frame: At one year

  32. Short Form 36 (SF-36) questionnaire at one year

    Quality of life assessed using the Short Form 36 (SF-36) Health Survey questionnaire

    Time frame: At one year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U; CULPRIT-SHOCK Investigators. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017 Dec 21;377(25):2419-2432. doi: 10.1056/NEJMoa1710261. Epub 2017 Oct 30. PubMed 29083953 ↗
  • Authors/Task Force members; Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29. No abstract available. PubMed 25173339 ↗
  • Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, Eitel I, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Jobs A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Hunziker L, Savonitto S, Torremante P, Vrints C, Schneider S, Zeymer U, Desch S; CULPRIT-SHOCK Investigators. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med. 2018 Nov 1;379(18):1699-1710. doi: 10.1056/NEJMoa1808788. Epub 2018 Aug 25. PubMed 30145971 ↗
  • Overtchouk P, Pascal J, Lebreton G, Hulot JS, Luyt CE, Combes A, Kerneis M, Silvain J, Barthelemy O, Leprince P, Brechot N, Montalescot G, Collet JP. Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support. EuroIntervention. 2018 Apr 6;13(18):e2160-e2168. doi: 10.4244/EIJ-D-17-01014. PubMed 29400656 ↗
  • Muller G, Flecher E, Lebreton G, Luyt CE, Trouillet JL, Brechot N, Schmidt M, Mastroianni C, Chastre J, Leprince P, Anselmi A, Combes A. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Med. 2016 Mar;42(3):370-378. doi: 10.1007/s00134-016-4223-9. Epub 2016 Jan 29. PubMed 26825953 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Oct 2026, 60 months after the start.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 60 months is above that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2019
First posted
Dec 3, 2019
StartActual
Oct 14, 2021
Primary completionEst.
Oct 14, 2026
CompletionEst.
Oct 14, 2027
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04184635
Responsible party
Sponsor
First posted
Dec 3, 2019
Start date
Oct 14, 2021
Primary completion
Oct 14, 2026 (estimated)
Completion
Oct 14, 2027 (estimated)
Last update
Jan 14, 2025

Study contacts

Alain COMBES, MD, PhD
Contact
alain.combes@aphp.fr
01.42.16.38.16 ext. +33
Gilles MONTALESCOT, MD, PhD
Contact
gilles.montalescot@aphp.fr
01.42.16.30.07 ext. +33
Alain COMBES, MD, PhD
principal investigator · Centre Hospitalier Universitaire Pitié-Salpêtrière Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion